Want to see LNSR full AI Analyst Report?
LENSAR (LNSR) Stock Price & Analysis
LNSR Stock Chart & Stats
- Day’s Range
- $5.60 - $5.86
- 52-Week Range
- $4.95 - $12.94
- Previous Close
- $5.84
- Volume
- N/A
- Average Volume (3M)
- 39.57K
- Market Cap
- $71.75M
- Enterprise Value
- $134.08M
- Total Cash (Recent Filing)
- $13.56M
- Total Debt (Recent Filing)
- $2.38M
- Price to Earnings (P/E)
- 4.5
- Beta
- 0.97
- Next Earnings
- Nov 10, 2026 (Est.)
- EPS Estimate
- -0.1
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Recurring Revenue Strength
A high and growing recurring-revenue mix makes demand more predictable than system sales alone and can support steadier cash generation over time. This recurring base also deepens customer relationships and provides a durable foundation for continued expansion in ophthalmology procedures and services.
Procedure Growth And Market Share
Rising procedure revenue and volume indicate increasing utilization of LENSAR’s platform, while higher U.S. share suggests competitive traction in its core market. Sustained clinical adoption can reinforce revenue growth because more procedures expand demand for related systems, software, and services.
Installed Base Expansion
Expansion of the installed base increases the company’s footprint among eye-care providers and creates a larger platform for recurring procedure-related revenue. Growing ALLY adoption also supports customer familiarity, market penetration, and future opportunities to deepen utilization across existing accounts.
Bears Say
Negative Cash Generation
Persistent negative operating and free cash flow means reported earnings have not yet translated into internally generated liquidity. If cash burn continues, LENSAR may have less flexibility to fund commercial investment, support growth initiatives, or absorb operating volatility without additional financing.
Profitability Durability Concerns
The recent improvement in net income is encouraging but not yet fully established as an operating trend because EBIT remains negative and prior years show recurring losses. The disconnect between operating and net results makes future profitability more dependent on the quality and repeatability of non-operating items.
Non-Recurring Margin Support
Underlying gross margin was lower than the reported figure because a tariff refund provided a one-time benefit. Although the adjusted margin still improved year over year, reliance on non-recurring support means reported margin strength may not be fully repeatable and requires continued operating execution.
LENSAR News
Lensar Faces Heightened Litigation Risk as Shareholders Challenge Merger Disclosures in Delaware
Lensar Inc (LNSR) has disclosed a new risk, in the Share Price & Shareholder Rights category. Lensar Inc. faces elevated litigation risk as certain purported shareholders challenge the adequacy of
LNSR FAQ
What was LENSAR’s price range in the past 12 months?
What is LENSAR’s market cap?
When is LENSAR’s upcoming earnings report date?
How were LENSAR’s earnings last quarter?
Is LENSAR overvalued?
Does LENSAR pay dividends?
What is LENSAR’s EPS estimate?
How many shares outstanding does LENSAR have?
What happened to LENSAR’s price movement after its last earnings report?
Which hedge fund is a major shareholder of LENSAR?
What is the TipRanks Smart Score and how is it calculated?
LENSAR Stock Smart Score
Company Description
LENSAR
LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser systems for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System, Europe, Asia, South Korea, and internationally. The company offers the LENSAR Laser System, which incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes by providing imaging, procedure planning, design, and precision. It also provides ALLY Robotic Cataract Laser System, a compact cataract treatment system that is designed to allow surgeons to perform sterile laser-assisted cataract surgery in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Nicholas T. Curtis
- Employees
- 150
- Website
- www.lensar.com
- Address
- 2800 Discovery Drive, Orlando, FL, 32826, US
LENSAR (LNSR) Earnings & Revenues
LNSR Earnings Call
Earnings Call SentimentPositive
The call presented clear operational and financial improvements: double‑digit revenue growth (18% total, 20% recurring), strong procedure growth (23% procedure revenue, 13% volume), expanding installed base and the best adjusted EBITDA to date. These positives are tempered by a lower cash balance, reliance on a $1.1M tariff refund that boosted gross margin, near-term seasonality, expected normalization of operating expenses as commercial investments resume, and some timing/pricing uncertainty around backlog and distributor re-engagement. On balance, the fundamental business momentum (recurring revenue mix, procedures, ALLY adoption and profitability improvement) outweighs the short-term risks and one-time items.
View all LNSR earnings summariesLNSR Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 2 | 5 | 15 |
| Technical Analysis | 2 | 5 | 3 |
| Moving Averages | 0 | 0 | 12 |












